Positron Emission Tomography with 18F Fluorodeoxyglucose for Primary Lymphoma of Bone.
- Author:
Nam Don KIM
1
;
Yeon Hee PARK
;
Seung Seog KI
;
Yong Jin PARK
;
Heoyng Joon KIM
;
Baek Yeol RYOO
;
Heung Tae KIM
;
Sungeun KIM
;
Gi Jeong CHEON
;
Chang Woon CHOI
;
Sang Moo LIM
Author Information
1. Department of Interual Medicine and Nuclear Medicine1, Korea Cancer Center Hospital Seoul. Korea. cylabe@kcchsun.kcch.re.kr
- Publication Type:Case Report
- Keywords:
primary bone lymphoma;
evaluation;
FDG-PET
- MeSH:
Drug Therapy;
Electrons*;
Fluorodeoxyglucose F18*;
Humans;
Lymphoma*;
Magnetic Resonance Imaging;
Neoplasm, Residual;
Positron-Emission Tomography*
- From:Korean Journal of Nuclear Medicine
2003;37(5):331-335
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Accurate assessment of the lesion after treatment of patients with bone lymphoma is difficult. In this patient who demonstrated complete remission after chemotherapy, the regions of fluorine-18 fluorodeoxyglucose ( (18) FFDG) PET uptake diminished more rapidly following therapy, indicating a complete response at much earlier stage than did Magnetic Resonance Imaging (MRI) or CT based findings. With the conventional methods, such as MRI and CT, it was difficult to assess whether the residual tumor tissue was viable or not. Decision to complete response is very important in patients with lymphoma to plan the further treatment. We experienced a patient with primary lymphoma of bone who revealed complete response to chemotherapy on (18) FFDGPET while CT showed persistent destructive bone lesion. Thus, (18) FFDGPET study after therapy may be superior to CT in the evaluation of response to treatment in primary lymphoma of bone.
